BRIEF — Aimmune trading higher on full PALISADE publication

US biotech Aimmune Therapeutics has published full results from its 554-patient Phase III PALISADE trial of AR101 as a treatment for peanut allergy.

The company announced last month that the  trial had met its primary endpoint but shares in the company closed 6% down on the day due to investor concern at the dropout rate in the study. More than 20% of children discontinued treatment, mostly due to drug-related adverse events.

Monday’s full publication of the results at the 2018 American Academy of Allergy, Asthma and Immunology–World Allergy Organization Joint Congress were better received in the stock market, with shares in Aimmune rising by 4% to $35.39 in the first 90 minutes of trading.